Bioton

Bioton FCF/Debt

The Free Cash Flow to Debt Ratio of Bioton (BIO.WA) as of Oct 11, 2026 is 3.98 %. In the previous year, Free Cash Flow to Debt Ratio was 43.69 % — a change of -90.89% (lower).

FCF/Debt

3.98 %

YoY

-90.89%

Last updated:

Free Cash Flow to Debt Ratio of Bioton is 2025 3.98 % . Free Cash Flow to Debt Ratio of Bioton was 2024 43.69 % . It decreases by -90.89% lower compared to the previous year.

The Bioton FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-13.95 PLN
Jan 1, 2019
-5.30 PLN
Jan 1, 2020
33.85 PLN
Jan 1, 2021
-6.70 PLN
Jan 1, 2022
34.69 PLN
Jan 1, 2023
-6.61 PLN
Jan 1, 2024
43.69 PLN
Jan 1, 2025
3.98 PLN
The Bioton FCF/Debt history
YEARFCF/DebtYoY
3.98 %-90.89%
43.69 %-760.98%
-6.61 %-119.05%
34.69 %-618.19%
-6.70 %-119.78%
33.85 %-738.96%
-5.30 %-62.03%
-13.95 %+71.08%
-8.15 %+1,371.91%
-0.55 %-72.35%
-2.00 %-128.73%
6.97 %—
Access this data via the Eulerpool API

Bioton Stock analysis

What does Bioton do? Bioton SA is a leading Polish biotechnology company specializing in the development of innovative drugs, diagnostics, and medical devices. The company was founded in 1989 and has since achieved remarkable success. Bioton is headquartered in Poland and employs approximately 1000 people worldwide. The company is listed on the Warsaw Stock Exchange and is supported by renowned investors. Business model Bioton operates various business divisions, including research and development, production, sales, as well as marketing and distribution. The company collaborates closely with leading academic institutions and research organizations and invests significant resources in the development of new groundbreaking technologies and products. The company's products and services are distributed and used in over 60 countries worldwide. Divisions Bioton is divided into three main business sectors, including biopharmaceuticals, diagnostics, and medical devices. Biopharmaceuticals Bioton is known for its biopharmaceuticals, particularly insulin and insulin analogs. Insulin is a hormone produced by the body to regulate blood sugar levels. Bioton offers various insulin products, including human insulin, insulin glargine, and insulin aspart. These products are approved for the treatment of diabetes mellitus and are distributed in over 50 countries worldwide. Diagnostics Bioton is also involved in the development and production of diagnostics. The company offers various testing systems for the diagnosis of infectious diseases, allergies, and autoimmune diseases. The product line also includes in vitro diagnostics that are used for medical therapy monitoring and disease detection. Medical devices Bioton also manufactures and distributes medical devices such as insulin pumps and blood glucose meters. These devices are designed for people with diabetes and assist in accurate insulin dosing and blood sugar level monitoring. Products In addition to insulin and insulin analogs, Bioton also produces a wide range of other drugs, including growth hormones, as well as follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These hormones are used for the treatment of infertility. Bioton is also involved in the development of novel technologies such as RNA interference (RNAi) and genomic research. The company invests significantly in innovative research projects aimed at the development of groundbreaking drugs and therapies. In conclusion, Bioton SA is a highly innovative biotechnology company with a wide range of products and a focus on research and development. The company operates in the global market and collaborates closely with renowned institutions and research organizations. Bioton's business model is based on the development of innovative technologies and products aimed at improving the quality of life for people worldwide. Bioton is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioton stock

Free Cash Flow to Debt Ratio of Bioton is 3.98 % in 2025.

Free Cash Flow to Debt Ratio of Bioton changed from 43.69 % to 3.98 %, representing a -90.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Bioton since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Bioton with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Bioton

All Key Metrics — Bioton